My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Muromonab Biosimilar, CD3 Monoclonal Antibody

Muromonab Biosimilar, CD3 Monoclonal Antibody

cluster of differentiation 3, CD3D, CD3E, CD3G

Catalog No. Product Name Size List Price (US$) Quantity
C054P Muromonab Biosimilar, CD3 Monoclonal Antibody 1 mg 250.00
C054P Muromonab Biosimilar, CD3 Monoclonal Antibody 5 mg 750.00
C054P Muromonab Biosimilar, CD3 Monoclonal Antibody 20 mg 2000.00
Description

C054P: Muromonab Biosimilar, CD3 Monoclonal Antibody

Recombinant mouse IgG2a Monoclonal Antibody.
Isotype: Mouse IgG2a kappa.
Source: The anti-human CD3 monoclonal antibody muromonab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade muromonab biosimilar specifically binds to the human T cell receptor CD3.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by muromonab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade muromonab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

Muromonab Biosimilar uses the same protein sequences as the therapeutic antibody muromonab.

Muromonab is a monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.

Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type 2a (IgG2a).

Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.

Related Links

See our Privacy Policy